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Introduction {#sec1}
============

Rhythmic oscillations in cellular activity are coordinated by genes that comprise the core circadian machinery ([@bib3]). The notion that circadian rhythm disruptions lead to an increased likelihood of mammary tumor development is supported by studies that female workers taking frequent night shifts have disrupted internal clocks and an increased risk of developing breast cancer (BC) ([@bib12], [@bib61], [@bib70]). It has been reported that circadian genes have anti-tumor roles in multiple cancer types ([@bib14], [@bib49], [@bib64]) and may act as tumor suppressors by regulating a wide variety of pathophysiological events, including cellular metabolism and pathogenesis of cancer ([@bib8], [@bib34], [@bib35]). Indeed, disrupted circadian rhythm likely affects multiple hallmarks of cancer, including proliferative signaling maintenance, cell death resistance, replicative immortality, invasion and metastasis activation, and energy metabolism reconfiguration ([@bib26]).

Epidemiological data also suggest that disrupted circadian rhythm is strongly associated with metabolic syndrome ([@bib67]). Multiple factors common to metabolic syndrome and its related disorders have been shown to promote BC tumor growth and progression ([@bib29]). For example, hyperinsulinemia, or elevated circulating insulin levels, is a hallmark of obesity and pre-diabetes and is associated with higher BC incidence and poor prognosis ([@bib15], [@bib23], [@bib25], [@bib33], [@bib36], [@bib66]). Moreover, multiple reports indicate that metabolic diseases differentially impact individual subtypes of BC ([@bib7], [@bib21], [@bib72]). Overall, despite current studies demonstrating a close relationship among circadian disruption, metabolic syndrome, and cancer progression, the mechanisms linking these together are not yet systematically established.

Circadian clocks are orchestrated by a gene network through transcriptional regulation ([@bib50]). Circadian-controlled genes are transcribed after initiation by the transcription factor heterodimer complex comprising Brain and Muscle Arnt-Like (BMAL) and Circadian Locomotor Output Cycles Kaput (CLOCK) ([@bib57]). Together with BMAL1 (gene name: *ARNTL*) and CLOCK, the core circadian genes comprise the machinery that implements the oscillations in cellular activity ([@bib3]). Therefore, BMAL1 is an essential clock gene affecting all rhythmic behaviors as the loss of BMAL1 ensures that the circadian heterodimer is disrupted ([@bib6]). A number of reports have documented the crosstalk between BMAL1 function and insulin signaling, mitochondrial function, and lipid metabolism in non-cancer tissues ([@bib5], [@bib11], [@bib30], [@bib37], [@bib38], [@bib40], [@bib41], [@bib43], [@bib77]). In addition, BMAL1 transcriptionally activates genes important for its own feedback loop ([@bib59]) as well as many cellular processes, including mitochondrial dynamics, cell cycle regulation, and stress responses ([@bib27], [@bib30], [@bib56]). Global and liver-specific knockout of BMAL1 resulted in hyperlipidemia and increased lipoprotein production ([@bib48]). However, the functional role of BMAL1 in BC cell metabolism and tumor progression remains largely unknown.

Understanding how circadian disruption and metabolic dysregulation influence BC can help elucidate the underlying biological mechanisms, especially in the basal-like (BL)/triple-negative BC (TNBC) subtype for which there is currently no effective therapeutic target. In this study, we developed two independent cell models, *in vitro* and *in vivo*, to investigate how the deficiency of intrinsic BMAL1 affects cellular metabolic homeostasis and tumor progression of TNBC. We demonstrate a previously unrecognized effect by tumor-intrinsic BMAL1 on shaping the mitochondrial fuel flexibility and anti-tumor landscape. Our observations provide insights into the mechanism underlying BMAL1-mediated TNBC suppression and evidence that BMAL1 downregulation in combination with hyperinsulinemic obesity exacerbates TNBC progression and aggressiveness. We discuss the implications of using BMAL1 as a marker, along with diet management, for cancer prevention and therapeutics.

Results {#sec2}
=======

Developing an *In Vitro* Cell Model to Investigate BMAL1 Function in TNBC {#sec2.1}
-------------------------------------------------------------------------

Circadian rhythms not only vary among different organisms but also can be unique in different tissue organs within the same organism ([@bib75]). Investigation across cancers originated from different tissues suggested that altered expression of clock genes often shows cancer type-specific pattern and is associated with oncogenic pathways, clinical outcomes, and molecular subtypes ([@bib74]). To examine the expression profile of canonical core circadian genes across different cancer types, we investigated The Cancer Genome Atlas (TCGA) Pan-Cancer datasets. Consistent with the corroborated link between circadian disruption and BC ([@bib4]), the expression of *ARNTL*/BMAL1 was significantly down-regulated in primary tumor samples compared with normal tissues in multiple cancer types, including BC ([Figure S1](#mmc1){ref-type="supplementary-material"}A). As BC is highly heterogeneous and can be classified into different molecular subtypes ([@bib51]), subsequent analysis using unsupervised hierarchical clustering revealed that the BL subtype has a distinct circadian gene expression profile among the PAM50 molecular subtypes ([Figure 1](#fig1){ref-type="fig"}A). Most tumors of BL subtype do not express receptors for estrogen, progesterone, and HER2, the major characteristics of TNBC. This subtype is more aggressive and has a poorer prognosis than other BC subtypes ([@bib63], [@bib65]). The average expression of the core circadian genes ([Figure 1](#fig1){ref-type="fig"}B) and *ARNTL*/BMAL1 ([Figure 1](#fig1){ref-type="fig"}C) in the BL and HER2-enriched subtypes was significantly lower compared with the other subtypes. We thereby sought to further study BMAL1 deficiency with the focus on BL/TNBC because circadian rhythm disruption may affect BC in a subtype-dependent manner.Figure 1Expression of Core Circadian Genes Is Altered in BC(A) The 1,097 BC patient samples from the TCGA database were analyzed via unsupervised hierarchical clustering to show circadian expression profiles among the PAM50 subtypes: Basal-like, HER2-enriched, Luminal A, Luminal B, and Normal-like.(B and C) The patient samples were analyzed for average expression of circadian genes (B) and *ARNTL* expression (C), grouped by BC subtypes.(D) Immunoblot analysis (left panel) of markers of active insulin signaling---phosphorylated AKT and phosphorylated IRβ---were examined to reflect relative levels of insulin signaling. GAPDH serves as a loading control. Quantification of phosphorylated AKT/total AKT and phosphorylated IRβ/total IRβ is shown relative to GAPDH levels, and signal in untreated cells is set to 1 (*right panel*). CIT: chronic insulin treatment.(E) Cells were entrained by serum shock. Total RNA was collected every 4 h and analyzed by qRT-PCR. Data are shown as mean ± SD; n = 3; one-way ANOVA with Tukey\'s post hoc test. The *GAPDH* mRNA level of untreated cells at 0 h is set to 1.(B, C, and E) N/S p \> 0.05; \*p \> 0.05; \*\*p \< 0.05; \*\*\*p \< 0.001. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

To identify a suitable *in vitro* cell model, we evaluated a panel of 51 BC cell lines. The gene expression profiles are in general agreement with our observations from the TCGA clinical samples, confirming that circadian gene expression levels differ among the BC subtypes. Among the BL/TNBC cell lines, MDA-MB-231 was selected for its low- to mid-range abundance of circadian gene expression ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and *ARNTL* message ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Next, to develop a metabolic phenotype, MDA-MB-231 cells were continuously passaged in media supplemented with insulin for more than 10 passages, referred to as chronic insulin treatment (CIT). To mimic the insulin levels in a post-meal, fed state during pre-diabetes (high insulin with normal glucose), CIT cells treated with 10 or 100 nM insulin were assayed to verify that these cells were no longer sensitive to additional insulin stimulation. As shown in [Figure 1](#fig1){ref-type="fig"}D, no strong increase in insulin signaling activation was observed in serum/insulin-deprived (24 h) CIT cells stimulated with a high concentration of insulin at 100 nM, indicating the development of insulin resistance. To examine the effect of CIT on circadian outputs, a serum shock procedure was applied to stimulate and synchronize oscillations of circadian genes ([@bib1]). Cells grown without insulin exhibited a standard *ARNTL* mRNA oscillation, whereas we observed decreased amplitude for short-term insulin treatment and an early peak for CIT ([Figure 1](#fig1){ref-type="fig"}E). Of note, we also tested the same assay with additional cell lines having different abundance of endogenous BMAL1 ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Alteration of *ARNTL* mRNA oscillation was again observed in another TNBC cell line BT549 ([Figure S2](#mmc1){ref-type="supplementary-material"}B), as well as progesterone receptor-positive MCF7 cells ([Figure S2](#mmc1){ref-type="supplementary-material"}C), suggesting that the effect of short-term insulin and CIT on *ARNTL* mRNA oscillation is common. However, the alteration pattern may vary with different cell types.

The Interplay between BMAL1 and Mitochondrial Adaptations to CIT {#sec2.2}
----------------------------------------------------------------

The molecular interplay between circadian rhythms and cellular metabolism has been delineated as circadian genes control the nicotinamide adenine dinucleotide (NAD^+^) salvage pathway ([@bib44]). Thus, we conducted oscillating circadian-controlled NAD^+^ assays ([@bib55]) with untreated and CIT cells. CIT cells showed a faster peak time and a higher steady-state NAD^+^/NADH ratio than those in insulin-responsive MDA-MB-231 cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A), demonstrating the links among insulin signaling, circadian output, and cellular metabolism. Also, the oxidation of NADH to NAD^+^ links the tricarboxylic acid (TCA) cycle to ATP generation in mitochondria. Based on the above results, we tested the hypothesis that mitochondrial activity may partake in BMAL1 regulation. In ρ^0^ cells (depleted of mitochondrial DNA), we observed a significant decrease in the steady-state BMAL1 protein levels ([Figure S3](#mmc1){ref-type="supplementary-material"}B) and mRNA levels of *ARNTL*/BMAL1, along with its direct target *NAMPT*, irrespective of CIT ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Unlike in MDA-MB-231 cells ([Figure 1](#fig1){ref-type="fig"}E), there was no detectable difference in *ARNTL* message oscillation between untreated and CIT ρ^0^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}D). We concluded that the mitochondrial activity is indispensable for the expression and CIT-mediated regulation of BMAL1 and its downstream NAD^+^-regulating target gene.

Next, we tested the state of mitochondrial respiration in the context of decreased BMAL1 expression. *ARNTL*-targeting small interfering RNA (siRNA) (siBMAL1) was designed and used to decrease BMAL1 abundance by nearly 90% ([Figure 2](#fig2){ref-type="fig"}A). In both untreated and CIT MDA-MB-231 cells, *ARNTL*knockdown produced higher levels of intracellular ATP ([Figure 2](#fig2){ref-type="fig"}B). Moreover, following CIT, BMAL1-knockdown cells produced a higher mitochondria-specific reactive oxygen species signal (reflecting electrons leaking from the electrochemical gradient) compared with control cells ([Figure 2](#fig2){ref-type="fig"}C). Together, these data suggested that BMAL1 regulates bioenergetic homeostasis and possibly other respiration outputs.Figure 2BMAL1 Mediates Pyruvate Utilization during Chronic Insulin Treatment(A) Representative immunoblot showing the CIT effect on BMAL1 in MDA-MB-231 cells. BMAL1-targeting or control siRNA was transiently transfected into untreated or CIT cells. Owing to different levels of protein abundance, BMAL1 blot with longer exposure time, compared with GAPDH blot, is shown.(B and C) (B) Intracellular levels of ATP and (C) mitochondrial superoxide were assayed in MDA-MB-231 cells grown without insulin (Untreated) or over 10 passages of insulin (100 nM, CIT) and then transiently transfected with control or BMAL1-targeting siRNA. Measurements are normalized to cell number. n = 3; independent samples t test.(D) Intracellular pyruvate was measured in MDA-MB-231 cells not treated or chronically treated with insulin (100 nM, CIT) and transfected with control or BMAL1-targeting siRNA. Pyruvate levels are normalized to cell number. n = 3.(E) One representative oxygen consumption rate (OCR) profile of Mito Stress Test with MDA-MB-231 cells containing control or BMAL1-targeting siRNA in media ± pyruvate.(F) Pyruvate is required for maximal respiration, calculated from (E). n ≥ 3.(G) The relative levels of mRNA encoding pyruvate-regulating enzymes from untreated or CIT MDA-MB-231 cells transfected with control or BMAL1/*ARNTL*-targeting siRNA, quantified using qRT-PCR. n = 3.(H) The basal respiration in untreated or CIT MDA-MB-231 cells transfected with control, BMAL1/*ARNTL*, or *PKM*-targeting siRNA were analyzed using Mito Stress Test. Measurements are normalized to cell number. n = 3; one-way ANOVA with Tukey\'s post hoc.(I) The capacity to oxidize pyruvate (left panel), glutamine (middle panel), and fatty acids (right panel) in control or siBMAL1-transfected, untreated, or CIT MDA-MB-231 cells was analyzed using the Mito Fuel Flex Test. n = 3; one-way ANOVA with Tukey\'s post hoc.(B--I) Data are shown as mean ± SD; \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001. (B--D and F--I) one-way ANOVA with Tukey\'s post hoc. See also [Figures S3--S6](#mmc1){ref-type="supplementary-material"}.

To pinpoint the involvement of BMAL1 in mitochondrial bioenergetics, oxygen consumption rate (OCR) was measured in untreated or CIT MDA-MB-231 cells. In control-knockdown cells, CIT increased OCR in a dose-dependent manner ([Figure S3](#mmc1){ref-type="supplementary-material"}E), and an opposite OCR pattern was observed in BMAL1-knockdown cells ([Figure S3](#mmc1){ref-type="supplementary-material"}F). BMAL1 knockdown increased basal respiration over control knockdown in untreated cells ([Figure S3](#mmc1){ref-type="supplementary-material"}G, left panel). Also, BMAL1 was required for CIT to increase maximum respiration, a measurement of respiratory capacity, in a dose-dependent manner ([Figure S3](#mmc1){ref-type="supplementary-material"}G, right panel). Given the fact that BMAL1 suppresses basal OCR in untreated cells and promotes maximal OCR in CIT cells, BMAL1 conceivably plays a key role in the mitochondrial metabolic adaptation to CIT.

We then investigated how BMAL1-mediated mitochondrial adaptations affect other metabolic parameters by measuring the levels of neutral lipid droplets, a nutrient source for cancer ([@bib53]). Before assaying, MDA-MB-231 cells were starved of glucose to promote fatty acid mobilization ([@bib54]). We observed that BMAL1 knockdown increased the amounts of lipid droplets in both untreated and CIT cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Also, another functional consequence of CIT and BMAL1knockdown was an increase in the sensitivity to metformin ([Figure S4](#mmc1){ref-type="supplementary-material"}B), a biguanide that causes oxidative stress by inhibiting mitochondrial complex I ([@bib42]). Last, by measuring extracellular acidification rate, we concluded that neither BMAL1 nor CIT impacted glycolytic activity ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4E) in MDA-MB-231 cells.

Pyruvate Links BMAL1 to Mitochondrial Bioenergetics {#sec2.3}
---------------------------------------------------

Pyruvate is a key link between glycolysis and TCA cycle ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Based on the above-mentioned results, we hypothesized that BMAL1 serves a distinct role in regulating pyruvate utilization in untreated and CIT cells. To address this possibility in different BC cells, intracellular pyruvate levels were measured in MDA-MB-231, along with BT549 and MCF7 cells. As we observed in MDA-MB-231 cells (shown in [Figure 2](#fig2){ref-type="fig"}A), CIT did not affect steady-state level of BMAL1 in either BT549 or MCF7 cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B). However, CIT increased pyruvate levels in control (without BMAL1 knockdown) MDA-MB-231 ([Figure 2](#fig2){ref-type="fig"}D) and BT-549 ([Figure S5](#mmc1){ref-type="supplementary-material"}C) cells compared with their untreated cells. Also, pyruvate level was not affected by BMAL1 knockdown in untreated MDA-MB-231 cells ([Figure 2](#fig2){ref-type="fig"}D). In contrast, BMAL1 knockdown in CIT cells decreased pyruvate levels in all three (MDA-MB231, BT549, and MCF7) cell lines ([Figures 2](#fig2){ref-type="fig"}D, [S5](#mmc1){ref-type="supplementary-material"}C, and S5E), suggesting that BMAL1 suppresses pyruvate utilization during CIT adaptation. We then measured OCR in the presence and absence of external pyruvate in MDA-MB-231 cells ([Figure 2](#fig2){ref-type="fig"}E). As expected, the increased maximal respiration by BMAL1 knockdown depended on external pyruvate availability ([Figure 2](#fig2){ref-type="fig"}F).

Because BMAL1 is a transcription factor, we posited that BMAL1 regulates genes that metabolize pyruvate ([@bib16]). We found that BMAL1 knockdown reduced the expression of pyruvate kinase (*PKM*) and pyruvate carboxylase (*PC*) (converting phosphoenolpyruvate to pyruvate and converting pyruvate to oxaloacetate, as shown in [Figure S5](#mmc1){ref-type="supplementary-material"}A) in untreated MDA-MB-231 cells ([Figure 2](#fig2){ref-type="fig"}G). In comparison, BMAL1 knockdown also markedly decreased *PKM*, *PC*, and *PDK4* mRNA levels in CIT BT549 ([Figure S5](#mmc1){ref-type="supplementary-material"}D), but only showed relatively minor effect in MCF7 cells ([Figure S5](#mmc1){ref-type="supplementary-material"}F), suggesting a context-dependent role of BMAL1 in regulating pyruvate metabolism enzyme expression in different BC cells. To test if the effects of BMAL1 on OCR are mediated through its regulation of PKM abundance, we applied *PKM*-targeting siRNA to lower PKM expression in MDA-MB-231 cells and assayed for mitochondrial respiration activity. Consistently, PKM knockdown increased OCR in untreated cells, but decreased OCR in CIT MDA-MB-231 cells, mimicking the effects seen in BMAL1knockdown ([Figure 2](#fig2){ref-type="fig"}H). The decreased PC activity could also render pyruvate less available to mitochondria ([@bib52]). Together, these findings underscored a specific role of BMAL1 in regulating pyruvate metabolism.

To corroborate that BMAL1 affects substrate utilization, specific inhibitors were used to block three major mitochondrial fuels: glutamine, long-chain fatty acids, and pyruvate. Mito Fuel Flex assays demonstrated that BMAL1 knockdown altered substrate capacity, or the ability of cells to increase oxidation of particular fuel to compensate for inhibition of alternative fuels. Specifically, BMAL1knockdown increased glutamine and fatty acid oxidation capacity in both untreated and CIT cells ([Figure 2](#fig2){ref-type="fig"}I, middle and right panels), indicating that BMAL1 suppresses glutamine and fatty acid utilization in MDA-MB-231 cells. However, BMAL1 knockdown increased the capacity of pyruvate oxidation under CIT, but decreased it in the insulin-sensitive cells ([Figure 2](#fig2){ref-type="fig"}I, left panel). Finally, compromised BMAL1 decreased pyruvate ([Figure S6](#mmc1){ref-type="supplementary-material"}A), but not glutamine ([Figure S6](#mmc1){ref-type="supplementary-material"}B) and fatty acid ([Figure S6](#mmc1){ref-type="supplementary-material"}C), dependency in mitochondria of CIT cells. These results demonstrated that BMAL1 regulates substrate usage and that CIT cells require BMAL1 to suppress substrate flexibility. This is consistent with our observations that BMAL1 knockdown mediates reduction of message abundance of key pyruvate metabolism-regulating enzymes ([Figure 2](#fig2){ref-type="fig"}G). Altogether, we surmised that CIT and BMAL1 counterbalanced the regulation of mitochondrial activity. This observed dual regulation of pyruvate by both BMAL1 and insulin would explain how insulin context alters the effect by BMAL1 on tumor cell metabolism.

BMAL1 Suppresses HFD-Induced Tumor Growth *In Vivo* {#sec2.4}
---------------------------------------------------

To further establish whether BMAL1 regulates tumor progression *in vivo*, we used wild-type female C57BL/6 mice coupled with mouse mammary tumor E0771 cells orthotopically implanted in syngeneic lean and obese mice ([Figure S7](#mmc1){ref-type="supplementary-material"}A). The advantage of using an allografted syngeneic mouse tumor model over an MDA-MB-231-xenografted NSG mouse model is that C57BL/6 mice are better responsive to high-fat diet (HFD) feeding (NSG mice are, but only with litter reduction, [@bib2]) and that we are able to study the interaction between cancer cells and their surrounding tumor microenvironment in an immunocompetent animal model. The E0771 cells were derived from a spontaneously developed TNBC in C57BL/6 mice ([@bib19], [@bib73]). Parental E0771 cells are poorly metastatic when compared with 4T1 cells ([@bib31]) and have homozygous mutations in *Trp53* and *Kras* genes ([@bib72]) with a detectable BMAL1 expression ([Figure 3](#fig3){ref-type="fig"}A, inset). When mice reached young adulthood at the age of 8 weeks, they were separated into two groups: HFD or low-fat diet (LFD) ([@bib18]). These two diets had equal calories and sucrose for consistent chow palatability and to ensure consistent caloric intake. HFD comprised 60% fat, whereas LFD had 10%. Fasting insulin and glucose levels were measured before starting the diets and 4 weeks after consuming either HFD or LFD. The results showed that LFD did not cause a notable change in fat mass and fasting insulin levels compared with measurements before starting the diet; however, both increased in HFD-fed mice without affecting fasting glucose levels ([Figure S7](#mmc1){ref-type="supplementary-material"}B). To test whether the lack of hyperglycemia in HFD-fed mice is due to hyperinsulinemia, which mimics pre-diabetic state, an oral glucose tolerance test was performed. Following glucose feeding after a starvation period, blood glucose levels spiked faster and remained high longer in HFD-fed mice compared with the mice with LFD ([Figure S7](#mmc1){ref-type="supplementary-material"}C). The HFD-fed mice also displayed higher body weight gained than LFD-fed mice, even though food intake did not differ ([Figures S7](#mmc1){ref-type="supplementary-material"}D and S7E).Figure 3BMAL1 Suppresses HFD-Promoted Tumor Growth(A) Palpable parental (left panel) or shBMAL1 (right panel) tumors were measured in LFD- and HFD-fed mice. n = 4--6; independent samples\' t test at each time point. Inset features immunoblot analysis of parental E0771 and E0771 with stable knockdown of BMAL1. Italicized numbers indicate relative BMAL1 expression level.(B) Tumor volumes from parental and BMAL1-knockdown E0771 cells in LFD- and HFD-fed mice were analyzed at day 28 after implantation (left panel). Representative tumor images are shown (right panel). n = 4--6.(C) Formalin-fixed tissue sections from tumors derived from parental and BMAL1*-*knockdown E0771 cells in LFD- and HFD-fed mice were stained with anti-Ki67 antibody. % Ki67+ cells were calculated as Ki67-positive cells divided by total cells (left panel). Representative images of stained tumor tissues are shown (right panel). n = 3. Scale bar, 200 μm; red scale bar, 100 μm (inset).(D) Number of lung nodules of parental or BMAL1*-*knockdown E0771 cells per mouse were counted in LFD- and HFD-fed mice (left panel). Representative image of lung lobes with metastatic nodules are shown (right panel); black scale bar, 3 mm; white scale bar in inset, 2 mm. n ≥ 4.(E) Relative maximum OCR was calculated for primary E0771 tumors of engrafted cells at passage 2 after extraction from tumors in LFD- and HFD-fed mice. n ≥ 4.(B--E) Data are shown as mean ± SD; \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001; \*\*\*\*p \< 0.0001; one-way ANOVA with Tukey\'s post hoc. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

After confirming HFD-induced obesity/hyperinsulinemia, the fourth mammary fat pad on the right side of lean or obese mice was implanted with parental E0771 cells or E0771 cells with stable BMAL1 knockdown. The mice were maintained on their respective diet for an additional 4 weeks. In general, HFD accelerated tumor progression over LFD ([Figure 3](#fig3){ref-type="fig"}A). Upon tumor harvest, BMAL1-knockdown E0771 tumors were not significantly different in size from parental tumors in lean mice, whereas they were larger than the corresponding tumors of parental cells in hyperinsulinemic mice ([Figure 3](#fig3){ref-type="fig"}B). The E0771/shBMAL1-derived tumors from HFD-fed mice showed the largest sizes among these four groups ([Figure 3](#fig3){ref-type="fig"}B, right panel). There was no notable difference in Ki67, a marker for cell proliferation, signals between tumors from the parental E0771 cells of LFD- and HFD-fed mice; however, BMAL1 knockdown decreased Ki67 signals in tumors harvested from lean, but not hyperinsulinemic, obese mice ([Figure 3](#fig3){ref-type="fig"}C). E0771/shBMAL1-derived tumors from LFD-fed mice had the least proliferative potential. We next examined whole lungs from obese and lean tumor-harboring mice as lungs are a common site of metastasis from E0771-derived mammary tumors ([@bib76]). Likewise, the obese tumor-bearing mice harbored more lung tumor nodules than the lean group ([Figure 3](#fig3){ref-type="fig"}D). In addition, BMAL1knockdown decreased the lung tumor nodules in LFD-fed tumor-bearing mice, yet significantly increased it in HFD-fed mice. Altogether, BMAL1 serves a non-canonical role of BMAL1 to suppress tumor progression and/or metastasis under hyperinsulinemic obese context.

Last, primary tumor cells from the orthotopically engrafted E0771 tumors were isolated, cultured, and assessed for mitochondrial respiratory function. It is important to note that, recapitulating findings in MDA-MB-231 cells *in vitro*, BMAL1 knockdown increased OCR in E0771 cells recovered from tumors of lean mice, whereas BMAL1 knockdown decreased OCR in E0771 cells from hyperinsulinemic obese mice ([Figure 3](#fig3){ref-type="fig"}E). This observation validates the importance of the combined effect of BMAL1-mediated metabolic adaptation and hyperinsulinemia as a determinant of TNBC progression and aggressiveness. In addition, using two different knockdown approaches in cells from two different species yielded comparable conclusion about the role of BMAL1 on mitochondrial bioenergetics, and these separate approaches likely ruled out potential off-target effect(s) of BMAL1 knockdown.

BMAL1 Influences Tumor Microenvironment in Hyperinsulinemic Obese Mice {#sec2.5}
----------------------------------------------------------------------

To further explore how BMAL1 and HFD-induced obesity interactively regulate tumor progression, we examined how the tumor was influenced by the microenvironment. Infiltration of F4/80 macrophage, a major component of the tumor microenvironment, was assessed by immunohistochemistry ([@bib24], [@bib28], [@bib45]). Inside the parental E0771-derived tumors, there were no notable differences in F4/80 signals regardless of diet; however, the E0771/shBMAL1-derived tumors in the hyperinsulinemic obese mice, compared with lean mice, exhibited significantly increased F4/80 signals ([Figure 4](#fig4){ref-type="fig"}A). Other prominent immune cells featured inside tumors are the CD8^+^ T cells, which play a protective role and are associated with better cancer prognoses and outcomes ([@bib20]). Tumors from hyperinsulinemic obese mice exhibited significantly decreased CD8^+^ T cell signals in the parental tumors than those in the lean mice ([Figure 4](#fig4){ref-type="fig"}B). Notably, there were no differences in CD8^+^ T cell recruitment in shBMAL1 tumors regardless of diet ([Figure 4](#fig4){ref-type="fig"}B).Figure 4Tumor-Expressed BMAL1 Influences Immune Cell Infiltration(A) F4/80 signal was quantified as the average area of F4/80 staining in non-overlapping sections of entire tumor and compared with other samples at the same magnification. n = 4 (left panel). Representative images of tissue sections are shown (right panel). Scale bar, 500 μm. Red scale bar, 125 μm (inset).(B) CD8 signal was quantified as the average area of CD8 staining in non-overlapping sections of entire tumor section and compared with other samples at the same magnification. n = 4. (A and B) Data shown as mean ± SEM; \*p \< 0.05; \*\*p \< 0.01; one-way ANOVA with Tukey\'s post hoc. Representative images of stained tissue are shown (right panel). Scale bar, 250 μm. Red scale bar, 100 μm (inset).(C) Gene Set Enrichment Analysis shows that expression of hallmark OxPhos gene set in TCGA BC primary tumors (n = 1,097) is inversely correlated with BMAL1 expression.(D and E) Kaplan-Meier curves show distal metastasis-free survival rate of patients selected according to BMAL1 expression from two independent datasets GEO: [GSE20685](ncbi-geo:GSE20685){#interref15} (D) and [GSE11121](ncbi-geo:GSE11121){#interref20} (E).(F) Hyperinsulinemia and BMAL1 regulate both internal metabolism and external microenvironment of TNBC. The intrinsic metabolism of TNBC reveals that BMAL1 and hyperinsulinemia have parallel yet distinct regulations of pyruvate and mitochondrial metabolism. The external TNBC microenvironment shows that BMAL1 and hyperinsulinemia in concert control immune cell recruitment and infiltration. The dotted line indicates a possible mechanism for immune cell recruitment via mitochondria-induced reactive oxygen species.

We further performed Gene Set Enrichment Analysis of human primary breast tumor data from TCGA and found that the oxidative phosphorylation (OxPhos) pathway is significantly upregulated in patient tumors with downregulated *ARNTL* ([Figure 4](#fig4){ref-type="fig"}C). Such observation is consistent with our findings of increased OCR during BMAL1 knockdown ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F). Together with [Figure S1](#mmc1){ref-type="supplementary-material"}C, our previously reported increase in OxPhos gene expression in TNBC and HER2-enriched BCs ([@bib10]) could be attributed to decreased *ARNTL* expression. In addition, although the metabolic states were not available, our analyses of two independent public datasets for human BC ([@bib32], [@bib62]) revealed that reduced *ARNTL* expression is associated with worse distal metastasis-free survival ([Figures 4](#fig4){ref-type="fig"}D and 4E).

Discussion {#sec3}
==========

Although HFD-induced obesity drives tumor growth through multiple mechanisms ([@bib47]), our findings support a new paradigm that reduced expression of *ARNTL*, a key component of the circadian clock, accelerates TNBC tumor growth and lung metastasis in an HFD-induced hyperinsulinemic obese context. Virtually, circadian clock disruption is detrimental to metabolic homeostasis in all cells. To underscore the importance of BMAL1 in the adaptation to hyperinsulinemia in BC cells, here we report that in two different TNBC cells in two distinct models, *in vitro* and *in vivo*, BMAL1 loss (BMAL1 crisis) decreases or increases mitochondrial respiration depending on hyperinsulinemia. In parallel, intrinsic BMAL1 oscillation is suppressed by short-term insulin exposure in a mitochondria-dependent manner in MDA-MB-231 cells. We propose a model in which the reduced BMAL1 expression cooperates with HFD-induced hyperinsulinemic obesity to accelerate TNBC tumor progression and lung metastasis through increased mitochondrial fuel flexibility and reshaped recruitment of macrophages and CD8^+^ T cells ([Figure 4](#fig4){ref-type="fig"}F).

Cancer cells exhibit metabolic plasticity, rewiring their metabolism to satisfy the demands of rapid cell proliferation and survival ([@bib22]). Mitochondria comprise a metabolic hub that is responsible for energy production, and also produce building blocks for cell growth by catabolizing glucose, amino acids, and fatty acids. Although we observed that circadian gene expression and mitochondrial activity appear to be interactive and counter-balanced, the detailed underlying mechanism is still not clear. It is plausible that metabolites from the mitochondria directly affect the transcriptional regulation of circadian genes. In addition, post-translational modifications also play a key role in regulating the expression of circadian genes, such as histone acetylation being required at promoters of BMAL1-CLOCK target genes ([@bib17]). Here, we introduce a link between circadian signaling and mitochondrial function by showing that BMAL1 transcriptionally regulates *PKM* expression. It hints that endogenous pyruvate production functions as a linchpin for BMAL1-mediated metabolic adaptations. As such, the combined effect of BMAL1 and hyperinsulinemic obesity on reshaping the tumor microenvironment is conceivably mediated by regulating intracellular pyruvate utilization. Our model on the combined effect of intracellular pyruvate and on promoting tumor progression is supported by reports that pyruvate metabolism is important in maintaining colon cancer stem cell proliferation ([@bib60]) and that PKM2-null mice display increased HFD-induced metabolic stress ([@bib13]).

Inflammation plays a key role in hyperinsulinemic obesity and metabolic disease ([@bib9], [@bib39]). In our model, it appears that cancer cell-intrinsic BMAL1 acts as a critical suppressor of F4/80 macrophage tumor infiltration under hyperinsulinemic obesity. Cancer cell BMAL1-mediated suppression of F4/80 macrophage infiltration thus has important implications for how anti-tumor immunity is impaired during hyperinsulinemic obesity. A causative role of immune cells in promoting tumor progression has been demonstrated ([@bib71]) as depleting inflammatory immune cells leads to rapid improvement in insulin sensitivity and glucose tolerance, which is associated with decreased local and systemic inflammation in obese mice ([@bib46]). The role of BMAL1 in immune cell recruitment is not yet elucidated. The observed decrease in CD8^+^ T cell recruitment in tumors harvested from HFD-fed mice is in agreement with findings in another report ([@bib68]). Considering such a decrease was not observed in BMAL1-knockdown tumors, one plausible function of BMAL1 is to prevent T cell exhaustion during obesity. Together, these data show that the immune cells surrounding the tumor are likely affected by the tumor cells\' metabolic flexibility. Cancer-associated fibroblasts have been shown to secrete pyruvate to support metabolism in the tumor ([@bib58]) and the BMAL1-suppressed pyruvate utilization we observed in CIT cells may contribute to the tumor microenvironment landscape. Furthermore, macrophages consume exogenous pyruvate, resulting in increased PD-L1 expression and suppressed anti-tumor immune cells ([@bib69]), providing a plausible mechanism of tumor-secreted pyruvate and uptake by immune cells.

In summary, our experimental results showed that BMAL1 suppresses TNBC progression in multiple ways: by maintaining the clock machinery and circadian rhythms, by suppressing hyperinsulinemia-dysregulated mitochondrial activity and pyruvate utilization, and by suppressing pro-inflammatory components of the immune microenvironment in the obese context. The latter roles could be attributed to non-canonical circadian functions of BMAL1. In this context, our results provide a compelling case for BMAL1 expression to be examined in patients with TNBC who also present with hyperinsulinemia in the clinic. TNBC tumors with BMAL1 crisis are predicted to have worse outcomes, especially during obesity/hyperinsulinemia. BMAL1 appears to act as a tumor suppressor in TNBC during obesity/hyperinsulinemia, underscoring the importance of understanding BMAL1-mediated mitochondrial metabolic reprogramming during CIT adaptation, which could be exploited pharmacologically or with diet management for better patient outcomes in the future.

Limitations of the Study {#sec3.1}
------------------------

There is ample evidence that the cellular circadian clock regulates more than just cell-intrinsic metabolic processes. Based on consistent observations using two distinct models of TNBC, both *in vitro* and *in vivo*, we propose a paradigm that BMAL1 serves as a metabolic switch on hyperinsulinemia-regulated mitochondrial activity to govern TNBC tumor progression. Indeed, there is a need to better link circadian biology to cancer risk. Although our findings provide insights regarding the non-canonical BMAL1 function, additional studies are needed to validate how BMAL1 loss (BMAL1 crisis) influences most cases of BC in different metabolic states and whether these insights can be leveraged into an effective therapy. Also, although we demonstrated that BMAL1 crisis confers advantages to cancer cells in both intrinsic metabolism and extrinsic inflammatory microenvironment during hyperinsulinemia, the underlying signaling mechanism among BMAL1 crisis, hyperinsulinemia, and tumorigenesis *in vivo* remains to be established.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods and Figures S1--S7
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